Hemoglobin A1c as a prognostic marker in XXXX undergoing primary angioplasty for @entity583 .

@entity1 @entity583 @entity6 @entity299
OBJECTIVES: We sought to determine the effect of hemoglobin A1c (HbA1c) on the outcomes of primary percutaneous coronary intervention (PCI) for @entity583 ( @entity583 ). BACKGROUND: @entity6 ( @entity6 ) can be diagnosed from a level of at least 6.5% on two separate occasions according to the American @entity6 Association (ADA) definition, which was updated in 2010. No data are available for the value of HbA1c in @entity1 with @entity583 treated with primary PCI. METHODS: A total of 374 consecutive @entity1 with @entity583 (mean age: 55.9  12.6 years, 318 @entity1 ), undergoing primary PCI between December 2009 and June 2010, were prospectively enrolled in this study. Blood samples for HbA1c were obtained on the first 24 h after admission. In-hospital follow-up was performed. By using new ADA criteria, @entity1 were classified into three groups: group I (HbA1c  <=5.6%, n=112); group II (HbA1c: 5.7-6.4%, n=180); and group III (HbA1c >= 6.5%, n=82). RESULTS: In-hospital mortality was higher in group III (11%) compared with group II (2.8%) and group I (0.9%; P=0.001). Major adverse @entity299 in the hospital were also higher in group III (12.2%) compared with other groups (group II, 5.6% vs. group I, 0.9%, P=0.003). After adjusting the baseline characteristics, HbA1c remained a strong independent predictor of the in-hospital mortality (odds ratio: 1.412; 95% confidence interval: 1.031-1.935, P=0.03). Hospital stay was also longer in group III than others (P=0.007). A total of 196 (63.6%) @entity1 without a history of @entity6 had elevated HbA1c of more than or equal to 5.7%, with 31 (10.1%) of them having HbA1c of more than or equal to 6.5%. CONCLUSION: HbA1c is an independent predictor of the in-hospital mortality in @entity583 treated with primary PCI. Apart from prognostic value, high HbA1c could be used for @entity6 diagnosis, which is supported by ADA definitions.
